Cmic Holdings Co., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 2006, the company has established itself as a leader in contract research and manufacturing services, catering to a diverse clientele in the life sciences sector.
Cmic Holdings is renowned for its comprehensive range of services, including drug development, clinical trial management, and regulatory affairs. What sets them apart is their commitment to innovation and quality, ensuring that clients receive tailored solutions that meet stringent industry standards. With a strong market position, Cmic Holdings has achieved significant milestones, including strategic partnerships and expansions that enhance its service offerings.
+21 vs industry average
Cmic Holdings Co’s score of 50 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cmic Holdings Co?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Cmic Holdings Co's reported carbon emissions
In 2025, CMIC Holdings Co., Ltd. reported total carbon emissions of approximately 72.6 million kg CO2e. This figure includes Scope 1 emissions of about 1.6 million kg CO2e, Scope 2 emissions of approximately 6.4 million kg CO2e, and significant Scope 3 emissions, which totalled around 64.6 million kg CO2e. The Scope 3 emissions breakdown includes investments (about 17.7 million kg CO2e), capital goods (approximately 8.5 million kg CO2e), and purchased goods and services (around 31.4 million kg CO2e). CMIC Holdings has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030, using FY2023 as the base year. Additionally, the company is committed to a 35% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change effectively. The company has demonstrated a proactive approach to sustainability, with its emissions data and reduction targets not being cascaded from any parent organization, indicating a direct responsibility for its climate impact. CMIC Holdings is positioned within the Pharmaceuticals, Biotechnology, and Life Sciences sector, underscoring its role in contributing to a more sustainable future.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cmic Holdings Co’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Cmic Holdings Co yet.
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Cmic Holdings Co
Frequently asked questions
Common questions about Cmic Holdings Co’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project